HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards

Executive Summary

FDA is using its new draft guidance on non-small cell lung cancer to once again stress the importance of using overall survival to prove efficacy and make clear that if progression-free survival measure is used, a “substantial and robust” effect should be shown.
Advertisement

Related Content

FDA Reiterates Preference For Overall Survival Data For Lung Cancer Approvals
ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up
ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up
Industry Presses FDA For More Specificity On Lung Cancer Study Endpoints
Industry Presses FDA For More Specificity On Lung Cancer Study Endpoints
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
“Underpowered” Cancer Trials Are Becoming “Major Problem” – FDA’s Pazdur

Topics

Advertisement
UsernamePublicRestriction

Register

PS053556

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel